Eupraxia Pharmaceuticals (EPRX) Net Cash Flow (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Net Cash Flow data on file, last reported at -$21.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 276.43% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was $31.0 million, a 540.08% increase from a year earlier, with the FY2025 full-year figure at $46.9 million, up 198.56% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$21.6 million, down from -$8.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for EPRX reached as high as $69.3 million in Q3 2025 and fell as low as -$21.6 million in Q1 2026.
• Historically, Net Cash Flow has averaged $3.2 million across 4 years, with a median of -$5.7 million in 2025.
• Across the five-year window, Net Cash Flow plunged 4001.35% in 2024 and jumped 567.41% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$6.0 million in 2023, then soared by 528.0% to $25.7 million in 2024, then plunged by 132.78% to -$8.4 million in 2025, then sank by 156.42% to -$21.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$21.6 million in Q1 2026, -$8.4 million in Q4 2025, and $69.3 million in Q3 2025.